Piper Jaffray says a new proprietary allergist
survey shows “massive upside” to sales potential and expectations for
Aimmune’s (NASDAQ:AIMT) peanut allergy drug.
Raymond James says the survey showed awareness and willingness to prescribe Palforzia.
Key quote: “While many have equated the opinions
of a few high profile critics with the overall market view, bears would
do well to pay attention to this feedback.”
AIMT shares are up 11.6% after hours to $22.85.
https://seekingalpha.com/news/3503130-aimmune-plus-11_6-percent-positive-allergist-survey
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.